+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07548476

Evaluating Combined Acupuncture and Virtual Exercise for Chemotherapy-Induced Peripheral Neuropathy in Bladder Cancer Patients Receiving Enfortumab Vedotin and Pembrolizumab

Led by Dana-Farber Cancer Institute · Updated on 2026-10-26

20

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combined acupuncture and exercise program to manage chemotherapy-induced peripheral neuropathy CIPN in adults with bladder cancer receiving enfortumab vedotin and pembrolizumab. CIPN can cause pain, numbness, and weakness in the hands and feet, often lasting long after chemotherapy ends. This study aims to assess the feasibility and initial effectiveness of these interventions in improving symptoms. Participants are randomly assigned to one of two groups one receiving acupuncture plus virtual exercise, and the other receiving virtual exercise alone. The exercise program is supervised virtually using an exercise bike and resistance bands, while acupuncture is performed weekly in clinic. The study lasts about 12 weeks and includes baseline and end-of-study clinic visits. During the study, participants complete questionnaires, sensory and physical performance tests, and cycling tests to measure changes in pain and neuropathy symptoms. Researchers monitor outcomes such as neuropathic pain scale scores, pain inventory, neurotoxicity, sensory testing, and treatment-related events. Weekly exercise adherence and program retention rates are also tracked throughout the 12-week period.

CONDITIONS

Brief Title

Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy

Research Team

C

Christina Dieli-Conwright, PhD, MPH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here